Figure 4.
Dysmenorrhea rapidly decreased from severe at baseline to mild by week 8 and was sustained through to week 24. Error bars show the upper and lower limit of 95% confidence intervals; * p values compare relugolix combination therapy vs a placebo with respect to change in NRS dysmenorrhea defined previous page scores by week 24. CT = combination therapy; LS = least squares.